Daily Brief Health Care: Moderna , HealthCare Global Enterprises, Acrobiosystems, eXoZymes, AstraZeneca, PHC Holdings , SUSMED, Zentek and more

• The Nasdaq 100 index tracks the 100 largest names listed on the Nasdaq Stock Exchange.
• In this insight, we have presented our expectations for ADDs/DELs for the upcoming annual reconstitution in December 2026.
• We expect threes changes at the December index rebal event and no intra-review changes before then.

• The Supreme Court has questioned medicine markups and sought government consideration of wider margin restrictions; a universal 16% cap is not yet established.
• Earnings exposure depends on drug billing, procurement economics, and contract terms, while restrictions on captive pharmacy purchases could create a separate volume risk.
• Investors should distinguish recoverable earnings pressure from weaker pricing power, then assess whether expansion returns justify existing valuation assumptions.

• Acrobiosystems is principally engaged in the research and development, production, and sales of recombinant proteins, antibodies, and analytical assay kits, seeking a primary listing on the Stock Exchange of Hong.
• The company ranked first among China-based providers and third globally in the recombinant protein market by revenue in 2025, serving all top 20 global pharmaceutical companies.
• The company reported revenue of RMB838,118 thousand for FY2025, though profit for the year decreased from RMB147,552 thousand in 2023 to RMB120,042 thousand in 2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• A cell-free biomanufacturing platform advances toward commercial validation.
• eXoZymes has spent nearly a decade developing engineered enzymes and cell-free production systems designed to manufacture molecules that can be difficult or uneconomic to source through conventional methods.
• Its asset-light approach retains ownership of the underlying process IP, enzymes, methods, and know-how, while outsourcing manufacturing to external partners. 

• AstraZeneca is putting $2 billion behind Summit Therapeutics in a transaction that could become more important than a straightforward biotech investment.
• AstraZeneca will purchase convertible preferred shares representing a common-stock price of $18.36 per share, a 10% premium to Summit’s five-day volume-weighted average price, while expanding the companies’ cancer-drug collaboration.
• Summit shares jumped 18% in after-hours trading following the announcement, while AstraZeneca shares were little changed.

• Toho Holdings’ rumored JPY 1,571 per share takeover bid (totaling over JPY 200 billion) is financially unfeasible in its current form. The offer sits below PHC’s market close of JPY 1,684 and its fair value of JPY 1,800–2,030, while Toho’s low-margin wholesale profile (1.1% operating margin) and a bitter poison-pill battle with activist 24% shareholder 3D Investment Partners severely restrict Toho’s debt-funding capacity.
• A Toho-PHC combination faces significant antitrust hurdles with the Japan Fair Trade Commission (JFTC). PHC’s Wemex subsidiary holds a dominant share of Japan’s medical IT and electronic medical record (EMR) market. Vertical integration with Toho—a major pharmaceutical wholesaler—creates direct conflict-of-interest risks and potential foreclosure of rival wholesalers, attracting rigorous regulatory scrutiny.
• PHC’s recent Q1 operating profit surge of 171% to JPY 10.4 billion is a temporary restructuring bump rather than a structural turnaround. The earnings jump was driven primarily by the divestiture of its unprofitable Continuous Glucose Monitoring (CGM) business and a temporary tariff refund, masking persistent organic growth declines in its core diagnostics and life sciences segments and high legacy integration costs from LSI Medience and Epredia.

Key points (machine generated)

• Susmed is a Tokyo Stock Exchange-listed company expecting significant revenue growth by June 2027 with its new insomnia disorder app.
• The company specializes in digital therapeutics (DTx), offering a modern treatment approach alongside traditional methods.
• Susmed operates in two segments: developing therapeutic apps for patients and healthcare professionals, and enhancing clinical trial efficiency for pharma companies using blockchain technology.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Zentek announced that it has shipped its first order of enhanced air filters to a federal facility under its standing offer with the Government of Canada.
• This marks a meaningful milestone for the segment.
• Last week, ZEN filed the technical report for its PEA on Albany, providing key details on the study.